^
    Back
    Association details:
    Biomarker:FBXW7 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Theranostics
    Title:

    Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer

    Published date:
    07/09/2020
    Excerpt:
    FBW7 mutations might be a potential biomarker predicting for response to the regorafenib/Mcl-1 inhibitor combination.
    DOI:
    10.7150/thno.45363